Skip to main content

Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy

Publication ,  Journal Article
Duvall, WL; Blazing, MA; Saxena, S; Guyton, JR
Published in: European Journal of Cardiovascular Prevention & Rehabilitation
January 1, 2002

Background Cardiovascular risk might be reduced by targeted changes in both low density and high density lipoprotein cholesterol (LDL-C and HDL-C). This dual strategy will require a well tolerated, effective regimen, as well as a better understanding of how HDL-C may be targeted. Design An open-label, uncontrolled, retrospective cohort study of combined statin–niacin therapy. Methods We reviewed all patients (n = 132) started on this combination in a referral lipid clinic over a 6.5-year period for tolerability, safety and effectiveness. Results Combined therapy was tolerated by 77% of patients. No serious adverse events attributable to medication were encountered. In drug-naive patients (n = 37), moderate doses of statin and niacin (mean 1180 mg/day) reduced LDL-C 31% and increased HDL-C 29% (P < 0.002, both comparisons). At niacin doses ≥ 1000 mg/day (mean 1480) added to a constant statin regimen (n = 29), HDL-C increased 20% (P < 0.001). Even at niacin doses < 1000 mg/day (mean 580, n = 23), HDL-C increased 13% (P < 0.05). Although mean HDL-C increased, the initial and final HDL-C distributions were broad and largely overlapping. Any chosen cutpoint for HDL-C goal would apply to only a minority of patients. The total/HDL cholesterol ratio had narrower distributions, as the percentage of patients with ratio < 5.0 increased from 17% to 67%. Conclusion Combined statin–niacin therapy lowers LDL-C and raises HDL-C with acceptable tolerance and safety. If treating LDL-C is the primary goal, consistent with current guidelines, then a strategy of targeting the total/HDL cholesterol ratio as a secondary goal is applicable to more patients than targeting HDL-C itself. © 2002, European Society of Cardiology. All rights reserved.

Duke Scholars

Published In

European Journal of Cardiovascular Prevention &amp; Rehabilitation

DOI

EISSN

1741-8275

ISSN

1741-8267

Publication Date

January 1, 2002

Volume

9

Issue

6

Start / End Page

339 / 347

Related Subject Headings

  • Cardiovascular System & Hematology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Duvall, W. L., Blazing, M. A., Saxena, S., & Guyton, J. R. (2002). Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy. European Journal of Cardiovascular Prevention &amp; Rehabilitation, 9(6), 339–347. https://doi.org/10.1177/174182670200900607
Duvall, W. L., M. A. Blazing, S. Saxena, and J. R. Guyton. “Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy.” European Journal of Cardiovascular Prevention &amp; Rehabilitation 9, no. 6 (January 1, 2002): 339–47. https://doi.org/10.1177/174182670200900607.
Duvall WL, Blazing MA, Saxena S, Guyton JR. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy. European Journal of Cardiovascular Prevention &amp; Rehabilitation. 2002 Jan 1;9(6):339–47.
Duvall, W. L., et al. “Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy.” European Journal of Cardiovascular Prevention &amp; Rehabilitation, vol. 9, no. 6, Jan. 2002, pp. 339–47. Scopus, doi:10.1177/174182670200900607.
Duvall WL, Blazing MA, Saxena S, Guyton JR. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy. European Journal of Cardiovascular Prevention &amp; Rehabilitation. 2002 Jan 1;9(6):339–347.

Published In

European Journal of Cardiovascular Prevention &amp; Rehabilitation

DOI

EISSN

1741-8275

ISSN

1741-8267

Publication Date

January 1, 2002

Volume

9

Issue

6

Start / End Page

339 / 347

Related Subject Headings

  • Cardiovascular System & Hematology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology